Company has informed the exchange about the unaudited financial results for the quarter ended June 30, 2026

Procter & Gamble Hygiene and Health Care Limited CIN: L24239MH1964PLC012971 Registered Office: P&G Plaza Cardinal Gracias Road, Chakala Andheri (E), Mumbai 400 099 Tel: (91-22) 6958 6000 Fax: (91-22) 6958 7337 Website: in.pg.com July 29, 2026 To, To, The Corporate Relations Department The Listing Department The BSE Limited The National Stock Exchange of India Limited Department of Corporate Services Exchange Plaza, Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400001 Mumbai – 400051 Ref:- Scrip Code:- 500459 Ref:- Scrip Code:- PGHH Dear Sir / Madam, Sub:- Unaudited Financial Results for the quarter ended June 30, 2026 We are pleased to inform you that at a meeting of the Board of Directors of the Company held today i.e. July 29, 2026, (commenced at 11:56 A.M. and ended at 12:45 P.M.), the Unaudited Financial Results for the quarter ended June 30, 2026 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended June 30, 2026; and b. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended June 30, 2026, furnished by Statutory Auditors of the Company. Kindly take the same on record. Thanking you, Yours faithfully, For Procter & Gamble Hygiene and Health Care Limited Flavia Machado Authorized Signatory KALYANIWALLA & MISTRYLLP CHARTERED ACCOUNTANTS REVIEW REPORT TO THE BOARD OF DIRECTORS PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED I. We have reviewed the accompanying Statement of Unaudited Financial Results of PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED ("the Compan. ") for the quarter ended June 30, 2026, and the notes thereon, (' the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, duly initialled by us for identification. This Statement which is the responsibility of the Company' Management has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on July 29 2026, has been prepared in accordance with the recognition and mea urement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' (' Ind A 34 ') prescribed under section 133 of the Companies Act, 2013 ("the Act") read with rele ant Rules issued thereunder as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review. 2. We conducted our review of the Statement in accordance with the Standard on Re iew Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion. 3. Based on our review conducted as above nothing has come to our attention that causes u to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. 4. Attention is drawn to the fact that the figures for the three months ended March 3 I, 2026, as reported in the Statement are the balancing figures between the audited figures in respect of the full pre iou financial year and the published year to date figures up to the end of the third quarter of the previous financial year which have been reviewed and not subjected to audit by us. For KALYA /WALLA & MISTRY LLP CHARTERED ACCOUNTA TS Firm Reg. o.: I04607W / WI00166 Oa,:r PARTNER M. o. 042454 UDIN: 26042454DZINTR8486 Mumbai: Jul. 29 2026. LLP IN : AAH • 3437 REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001 TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275 BusinUesses Proc&t Goarm bHlyog luno andH oalClahrL oi mited CIN:L 24239MH1964PLC012971 Rog,slOffiecer:eP d& GP laza CardiGnmacialsR oaCdh,k al AndheInE M)u,m b4a00i0 99 Te(l9 -12 26)9 568000 Fax·( 9-12 26)9 5783 37 Webs1l.ine .pg com 1,i nL akhs' STATEMEONFTU NAUDITFEIDN ANCRIEASLU LTFSO RT HEQ UARTEERN DE3D0 TJHU N2E0 26 (1) (2) (3) ()4 Preced,ngC orrespondP1r1e1vgYi eoaurs Particulars ThrMeoen hls ThrMeoen ths ThrMeoen lhs Ended Ended Ended Ended 301Jhu n2e0 26 31S IM arch2 026 30lJhu n2e0 25 31sM1a rc2h0 26 (Audited) (Unaudited) (Unaudited()A udited) (ReiNeort5 e below) 1 Income Sa!oefp roducts 88992 937 67 935 16 42 81 59 Otheorp erarehvneguen s 154 365 187 883 2 Revenfureo omp erations 89146 94132 937 03 42 90 42 3 Olohr1c1o1me 943 1 247 769 4 247 Totianlc o(m2e+ 3) 900 89 953 79 944 72 43 32 89 4 Expenses a) Cosolrr aawn pdo ckmianlge rcolnaslusm ed 200 24 17068 16440 73811 b) Purchaseso fslo ck-ln-lrdao( Tradgeodos )d 213 23 19324 202 48 823 96 c) ChangIen,s n venloorfn 111oissg hoeoddw so,rk-I -nporgresso nsdto c-ik-ntrade ( 33 22) ( 711) ( 25 71) 308 d) mploybeenee feixtpse nse 5436 5653 48 35 215 14 e) Fmonccoes ts 27 311 7 945 I) 0 precmatnladom no rt12e0x1Jopne nse 959 956 909 37 43 g) Adverti&ss ianlpger so moelxp,oenns se 83 32 132 54 68 73 522 72 h) Olhere xpenses 203 47 177 13 212 61 816 37 Toteaxlp enses 73126 7356 8 680 02 3166 26 5 Probfeifto trae(x 2 +3-4) 169 63 218 11 26470 1166 63 6 Incotmaeex x pense o) Curretna!x 43 89 5703 6662 299 95 b) D frr ed lax ( -53) 785 80 632 c) Prioyre atra xdju stmensl 10 522 366 4336 64 98 72 64 310 13 7 Proffoitrth poe ri(o5d)- 6 126 27 153 13 192 06 856 50 6 Othceorm preheinnsciov/m( eel oss) Hemsl hwailnl olbt e r edsaisfiedt op rofiolrl oss Remeasuroertm hedene lf ibneendep flialn s 143 92 ( 236) 573 Incotmaeex ff eocnta bove ( 36) ( 23) 59 ( 144) Totoatlh coorm prohoinnsciovm(cel /o sfsot)rh poe riod 107 69 ( 177) 429 9 Totcaolm preheinnsciov!meoet r h poe ri(o7d+ 8) 127 34 153 82 190 29 860 79 10 Pad-iupq ulslhya craep Ii(F la cVea ltu1 e0p eerq uisthya re) 3246 3246 32 46 32 46 11 OlherE quity 721 01 12 EarnipnegSrsh ar(eF avcael oufet1 0p oerq uisthya r(en)oa tn nual:i sed) a) Bos(,1c?11 ) 3890 471 7 5917 26366 b) Dilu(t1e?)nd 38_90 47.17 59.17 26386 Soca ccompannyoitntegost hfei nanrceisaull ts Business uso Notes: Tile above Unaudited F111ancIal Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respecbve meetings held on 29th July, 2026 and have been subjected to a limited review by the Statutory Auditors of the Company These financial results are prepared and published In accordance with Regulation 33 of the SEBI (Listing Obligebons and Disclosure Requirements) RegulalIons, 2015, as amended 2 The Unaudited Financial Results are prepared on accordance with the recognition and measurement principles laid down on lnd10n Accounting Standard 34 ·Intenm Financial Reporting• (Ind AS-34), as prescnbed under Section 133 of the Companies Act, 2013, read with relevant Rules issued thereunder and other accounting pnnc1ples generally accepted In India 3 The Company's operating segments under Ind AS 1 OB - Operating Segments are as follows -Health Care Products - Compns1ng of Ointment and Creams, Cough Drops and Tablets, -Hygiene Products -Comprising of Feminine Hygiene products and other skin care hygiene These ond1v1dual operallng segments have been aggregated into a single pnmary reportable segment I e manufacturing, trading and [Showing first 8,000 characters — download PDF for full document]